Skip to content
PICO Portalanswers from OpenAlex

Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program

PaperCitations, authors & open-access status

Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program is a paper indexed in PICO Portal from OpenAlex.

How many citations does Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program have?

PICO Portalcitation count

Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program has 122 citations in the OpenAlex counts PICO Portal stores.

When was Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program published?

PICO Portalyear

Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program has 2019 year in the PICO Portal index.

What is the open-access status of Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program?

PICO Portaloa status

Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program has hybrid oa status in the PICO Portal index.

What is the DOI of Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program?

PICO Portaldoi

The DOI for Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program is on the source record.

What is the PMID of Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program?

PICO Portalpmid

The PMID for Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program is on the source record.

What is the OpenAlex record for Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program?

PICO Portalopenalex

The OpenAlex for Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial